High prevalence of targetable drivers but poor outcomes in lung adenocarcinoma: a real-world cohort from the French West Indies - Takeaways - MDSpire

High prevalence of targetable drivers but poor outcomes in lung adenocarcinoma: a real-world cohort from the French West Indies

  • By

  • Régine Marlin

  • Emeline Colomba

  • Sabrina Pennont

  • Adel Zouzou

  • Marlyne Moranton

  • Nassim Boukadoum

  • Heriniaina Randriamiarisoa

  • Jean-Marc Rakotonarivo

  • Stefanos Bougas

  • Karim Fard

  • Soizic Masson

  • Moustapha Dramé

  • Jacques Jougon

  • Mihaela Aldea

  • Moustapha Agossou

  • May 4, 2026

  • 0 min

Share

  • 1

    Lung adenocarcinoma is the most common subtype of non-small cell lung cancer, with a high incidence in the French West Indies.

  • 2

    In a study of 159 patients, 58.5% presented with de novo metastatic disease, highlighting significant diagnostic delays.

  • 3

    Actionable oncogenic drivers were found in 62% of tumors, with EGFR mutations being the most prevalent at 33%.

  • 4

    Median overall survival for patients was 19.3 months, with targeted therapies showing longer progression-free survival.

  • 5

    The study emphasizes the need for improved early diagnosis and access to molecular testing in underserved Caribbean populations.

Original Source(s)

High prevalence of targetable drivers but poor outcomes in lung adenocarcinoma: a real-world cohort from the French West Indies

  • by Régine Marlin, Emeline Colomba, Sabrina Pennont, Adel Zouzou, Marlyne Moranton, Nassim Boukadoum, Heriniaina Randriamiarisoa, Jean-Marc Rakotonarivo, Stefanos Bougas, Karim Fard, Soizic Masson, Moustapha Dramé, Jacques Jougon, Mihaela Aldea, Moustapha Agossou

  • May 4, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy